
Single-enantiomer drugs represent an increasingly large share of new chemical entities, leading to approaches in asymmetric synthesis.
Nicholas B. Johnson, PhD, is a business development and marketing manager at Chirotech Technology Ltd.

Published: October 4th 2007 | Updated: